Citius Oncology (CTOR) Interest Expenses (2025 - 2026)
Citius Oncology (CTOR) recorded quarterly Interest Expenses of $16.9 million in Q1 2026, down 7.97% quarter-over-quarter from $18.4 million in Q4 2025.
Citius Oncology (CTOR) Interest Expenses (2025 - 2026) Analysis & Trends
Citius Oncology's Interest Expenses history runs 2 years deep, the most recent figure standing at $16.9 million for Q1 2026.
- In Q1 2026, Interest Expenses changed N/A year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $16.9 million (changed N/A YoY), while the FY2025 annual figure was $20.1 million, changed N/A from the prior year.
- Interest Expenses was $16.9 million for Q1 2026 at Citius Oncology, down from $18.4 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $18.4 million in Q4 2025 to a low of $57277.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 62.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 3.00 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 20.89 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 4.86 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Citius Oncology | 75.12 Mn | 72.49 Mn | 1.34 Mn | 16.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.93 Mn |
| Mar 31, 2026 | 16.93 Mn |
| Dec 31, 2025 | 18.39 Mn |
| Dec 31, 2025 | 18.39 Mn |
| Sep 30, 2025 | 57,277.00 |
| Sep 30, 2025 | 57,277.00 |
| Jun 30, 2025 | 160,755.00 |
| Jun 30, 2025 | 160,755.00 |